A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy

Haematologica

Volumn 92, Issue 4, 2007, Pages 493-501

  Dmoszynska, Anna ^a   Kloczko, Janusz ^b   Rokicka, Malgorzata ^b   Hellmann, Andrzej ^b   Spicka, Ivan ^b   Eid, Joseph E ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NONE

Author keywords

Anemia; C.E.R.A.; Chemotherapy; Erythropoietin; Multiple myeloma

Indexed keywords

ANTIHYPERTENSIVE AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; TRIAMCINOLONE; ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; ERYTHROPOIETIN; MACROGOL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INJECTION SITE DERMATITIS; LEUKOPENIA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SKIN ALLERGY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE; BLOOD CELL COUNT; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; ELECTROCARDIOGRAPHY; HALF LIFE TIME; HEMATOCRIT; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; FEMALE; HALF-LIFE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; RETICULOCYTES; TREATMENT OUTCOME;

EID: 34547682318     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10730     Document Type: Article

References (21)

1. Dammacco F, Luccarelli G, Prete M, Silvestris F. The role of recombinant human erythropoietin a in the treatment of chronic anemia in multiple myeloma. Rev Clin Exp Hematol 2002;Suppl 1:32-8.
2. Ludwig H, Pohl G, Österborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol 2004;2:233-41.
3. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
4. Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002;29 Suppl 8:40-4.
5. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-3.
6. Dammacco F, Silvestris F, Castoldi GL. The effectiveness and tolerability of epoetin a inpatients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998;28:127-34.
7. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin a in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-9.
8. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
9. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin b is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122:386-93.
10. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin a in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
11. Macdougall IC, Bailon P, Tare T, Pahlke W. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life [abstract]. J Am Soc Nephrol 2003;14:769A:SUPO1063[Abstract].
12. Macdougall IC. CERA (continuous erythropoiesis receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40.
13. Haselbeck A. Reigner B, Jordan P, Pannier A, Glaspy J. Pre-clinical and phase I pharmacokinetic and mode-of-action studies of CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent with an extended serum half-life. Proc Am Soc Clin Oncol 2003; 22:3006[Abstract].
14. Dougherty FC, Reigner B, Jordan P, Pannier A. Continuous erythropoiesis receptor activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004; 15 Suppl 3:592P [abstract].
15. Reigner B, Jordan P, Pannier A, Glaspy J. CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent: dose-dependent response in phase I studies. Proc Am Soc Clin Oncol 2003;22:2943[abstract].
16. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
17. Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002;3:121-30.
18. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16.
19. Brandt M, Lanzendörfer M, Frische J, Haselbeck A, Jarsch M. Different receptor binding activity of C.E.R.A. (continuous erythropoiesis receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006;21 Suppl 4:9:SO018[Abstract].
20. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin a and epoetin b. Clin Pharmacol Ther 1991;50:702-12.
21. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum D, Berdeaux D, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin α: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin α. Eur J Cancer 2005; 41:1140-9.